🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

opusip.co.uk/2022/04/07/kyn… Kynos Therapeutics gets boost for its drugs | Scotland | The Times Separately, Murgitroyd, the patent attorney,...

New investment in @KynosTxLtd. Excited to support the company as it seeks to become a leading player in the KMO field and develop inhibitors with the potential to transform patients' lives X multiple indications. #backinginnovation Damian Mole @epidarex Scottish Enterprise Innovate UK

New portfolio company @KynosTxLtd with @epidarex Scottish Enterprise Damian Mole Scott Webster. Excited to support & you can read more here: bit.ly/3NVhsmo. #backinginnovation 👇 thetimes.co.uk/article/kynos-…

@KynosTxLtd is unveiled today on #worldhealthday - thanks @scottjamesreid for covering the story. congratulations Damian Mole and team. scotsman.com/business/unive…

Kynos Therapeutics Emerges from Stealth with £9 Million Financing and Phase 1-ready KMO Inhibitor pharmaceuticaldaily.com/kynos-therapeu…

IP Group - visionary ventures @KynosTxLtd Damian Mole @epidarex Scottish Enterprise Innovate UK Very promising field with exciting prospects as a treatment option for so many conditions. Congratulations on this brilliant venture. Wish you all the success and bright future

Thanks for the great coverage from The Herald for our exciting news!

Every time I visit my friends in Europe, it makes me sadder and sadder about Brexit. #notangryjustdissappointed

I am humbled and delighted to share our most recent paper in Nature Immunology showing how hypoxemia (and consequent tissue hypoxia) alters innate immune responses in the lung in acute lung injury (ALI)/ ARDS rdcu.be/cOsSM. Summary of 6 years' worth of work @EdUni_MeetCIR 👇

Keith passed away from #Pancreatitis aged 46. His family have raised £2,100 in his memory, to support other families with further research, information and awareness. Thank you. Support future families in the honour of your loved one here: ow.ly/YhFk50JxXQb

We are delighted to welcome Alison Strutt to the Kynos leadership team! Alison is an exceptional addition to the company. #biotech #leadership #CFO #appointment kynostx.com/news/kynos-bui…

Kynos is rapidly building momentum towards the clinic. Alison’s experience across large pharma and #biotech covers #finance at the #operational level as well as a #strategic outlook. A breadth of skill and experience to support Kynos achieve a strong position in the near future.

We’re delighted to welcome Jean to Kynos as Chair. A fantastic addition to the company…exciting times ahead!

Have a look at our new paper in Heliyon We provide novel insight into the reciprocal relationship between the circadian rhythms and disease development (acute pancreatitis). Damian Mole Laboratory of Seasonal Biology doi.org/10.1016/j.heli…

Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underway | BioSpace biospace.com/article/kynos-… #jobs

Top 🔟 priorities for #pancreatitis 💣👇

1st Fringe show done. What a blast! Rebecca & I went all in for gut health, bowel awareness, breaking down barriers in talking about poo, science & wellbeing with our glamorous Susan Morrison & full house! #EdFringe2023 #ibd #crohns Crohn's & Colitis UK #poo @CODIfringe The Stand

thestand.co.uk/performance/15… One more show next Monday 21st! Thanks for all your support. Please come! Guts UK Charity Catherine McEwan Foundation @EdinUni_MeetCIR Edinburgh Medical School #fringe Institute for Regeneration and Repair

Our preprint “High resolution long-read telomere sequencing reveals dynamic mechanisms in aging and cancer” is now on bioRxiv. biorxiv.org/content/10.110…

In collaboration with Oxford Nanopore we developed a method to sequence entire human telomeres and determine bulk and chromosome arm-specific telomere length.